Fig. 2
From: Could patents interfere with the development of a cardiovascular polypill?
The 48 cardiovascular drugs in FDCs categorized by presence of generic competition and active patent listings in the United States or Canada. 1 This drug has one or more patents listed for it as a single formulation matched with an absence of generic alternatives in the concerned market (see Fig. 1). 2 While this drug has one or more patents listed for it as a single formulation, there are nevertheless generic alternatives available in that market (see Fig. 1)